Cosmo Pharmaceuticals Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	55.87	44.3	50.28	185.83	198.56
Short-Term Investments	1.21	17.99	-	52.7	-
Trading Asset Securities	65.68	80.68	-	2.43	23.65
Cash & Short-Term Investments	122.76	142.96	50.28	240.95	222.21
Cash Growth	-14.13%	184.36%	-79.14%	8.44%	4.40%
Accounts Receivable	24.14	18.94	28.45	38.61	24.45
Other Receivables	1.15	1.68	2.22	2.69	3.23
Receivables	25.3	20.62	30.67	41.3	27.68
Inventory	10.43	13.51	14.2	11.5	13.12
Prepaid Expenses	16.55	15.2	3.32	3.06	1.96
Other Current Assets	8.25	9.97	3.76	9.28	10.88
Total Current Assets	183.28	202.26	102.23	306.1	275.85
Property, Plant & Equipment	30.81	29.09	28.59	30.28	30.48
Long-Term Investments	17.34	31.84	3.29	8.27	49.08
Goodwill	24.01	24.01	24.01	24.01	24.01
Other Intangible Assets	155.62	161.66	116.15	360.89	369.31
Long-Term Deferred Tax Assets	19.89	18.72	19.83	14.68	18.64
Long-Term Deferred Charges	170.27	170.27	222.21	5.5	3.42
Other Long-Term Assets	11.44	8.94	9.75	9.87	9.78
Total Assets	612.64	646.77	526.05	759.59	805.56
Accounts Payable	8.36	9.1	8.78	7.59	8.3
Accrued Expenses	4.84	3.42	6.02	5.9	5.25
Current Portion of Long-Term Debt	0.14	0.14	0.14	171.07	0.13
Current Portion of Leases	0.57	0.68	0.76	0.76	0.76
Current Income Taxes Payable	0.62	19.95	2.17	2.29	3.25
Other Current Liabilities	11	14.98	7.25	7.35	3.55
Total Current Liabilities	25.52	48.27	25.12	194.95	21.24
Long-Term Debt	0.14	0.28	0.42	0.56	167.15
Long-Term Leases	3.41	1.1	0.52	1.21	1.88
Pension & Post-Retirement Benefits	0.58	0.65	0.56	0.41	0.48
Long-Term Deferred Tax Liabilities	93	90.81	92.61	97.1	99.75
Other Long-Term Liabilities	0.8	0.57	3.2	1.58	2.39
Total Liabilities	123.46	141.68	122.42	295.8	292.88
Common Stock	4.56	4.56	4.56	4.56	4.56
Additional Paid-In Capital	243.57	243.57	243.57	243.57	243.57
Retained Earnings	366.63	373.6	271.18	310.09	341.16
Treasury Stock	-91.72	-104.11	-101.31	-89.8	-65.56
Comprehensive Income & Other	-40.74	-19.28	-21.18	-11.49	-18.45
Total Common Equity	482.3	498.33	396.82	456.93	505.28
Minority Interest	6.88	6.76	6.81	6.86	7.4
Shareholders' Equity	489.18	505.09	403.62	463.79	512.68
Total Liabilities & Equity	612.64	646.77	526.05	759.59	805.56
Total Debt	4.27	2.2	1.84	173.6	169.92
Net Cash (Debt)	118.49	140.76	48.44	67.36	52.29
Net Cash Growth	-15.82%	190.61%	-28.09%	28.81%	16.96%
Net Cash Per Share	7.42	8.57	3.01	4.10	3.09
Filing Date Shares Outstanding	16.19	16.02	16.05	16.26	16.71
Total Common Shares Outstanding	16.19	16.02	16.05	16.26	16.71
Working Capital	157.76	153.99	77.11	111.15	254.61
Book Value Per Share	29.79	31.12	24.72	28.10	30.24
Tangible Book Value	302.68	312.67	256.66	72.04	111.96
Tangible Book Value Per Share	18.69	19.52	15.99	4.43	6.70
Land	27.14	24.64	25.01	24.97	24.02
Machinery	54.33	50.74	47.95	45.14	40.16
Construction In Progress	0.17	1.41	-	-	1.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.